Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CSTL - Castle Biosciences, Inc.
Market Cap 448.15M P/E - EPS this Y -4.70% Ern Qtrly Grth -
Income -30.8M Forward P/E -5.43 EPS next Y 12.90% 50D Avg Chg -
Sales 250.72M PEG - EPS past 5Y - 200D Avg Chg -23.00%
Dividend N/A Price/Book 1.19 EPS next 5Y - 52W High Chg -53.00%
Recommedations 1.40 Quick Ratio 8.82 Shares Outstanding 27.59M 52W Low Chg 81.00%
Insider Own 3.03% ROA -5.92% Shares Float 26.68M Beta -
Inst Own 89.17% ROE -7.82% Shares Shorted/Prior 1.46M/1.42M Price 16.79
Gross Margin 80.58% Profit Margin -12.28% Avg. Volume 846,548 Target Price 33.11
Oper. Margin -7.50% Earnings Date Jul 31 Volume 304,717 Change 0.42%
Healthcare | Diagnostics & Research | United States
About Castle Biosciences, Inc.

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Castle Biosciences, Inc. News
05/03/24 DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
05/02/24 Castle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ...
05/02/24 Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
05/02/24 Castle Biosciences Reports First Quarter 2024 Results
04/30/24 Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
04/17/24 We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn
04/11/24 Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
04/10/24 Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
04/10/24 Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
04/05/24 What Makes Castle Bioscience (CSTL) a Prospective Investment?
03:30 PM Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
04/02/24 Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
03/27/24 Castle Biosciences Announces Updates to its Board of Directors
03/25/24 Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
03/22/24 Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
03/20/24 Does Castle Bioscience (CSTL) Have Robust Growth Prospects?
03/19/24 Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
03/15/24 New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
03/12/24 Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
03/08/24 Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
CSTL Chatroom

User Image IN0V8 Posted - 23 hours ago

$CSTL Guggenheim raises target price to $32 from $29

User Image SouthHaus Posted - 1 day ago

$CSTL Just stuck a toe in here. At this moment I wish I had more capital to put to work in this one…but, I don’t. Here, where outdoor recreation…boating, golfing, fishing…and agriculture have people typically over-exposed to intense sunlight, skin cancers on head and neck are common. For those afflicted thusly, this science can be a life saver!

User Image Stock_Titan Posted - 1 day ago

$CSTL DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck https://www.stocktitan.net/news/CSTL/decision-dx-r-scc-significantly-improves-prediction-accuracy-of-3526uka5xjf5.html

User Image commoncentsinvestor Posted - 1 day ago

$CSTL Absolutely terrific report.

User Image Jiricek94 Posted - 1 day ago

$CSTL let's hope these earnings show more on the price then the last one ...

User Image Stock_Titan Posted - 1 day ago

$CSTL Castle Biosciences Reports First Quarter 2024 Results https://www.stocktitan.net/news/CSTL/castle-biosciences-reports-first-quarter-2024-aq4bkx19vjoo.html

User Image Doozio Posted - 2 days ago

Chop chop huckleberries n da 👑 of da $cstl on eps during 🧠⏰?

User Image berlinboy101 Posted - 2 days ago

$CSTL Lfg!!! Hopefully above $24 after today's ER

User Image AdiDasRom Posted - 04/29/24

$CSTL

User Image insiderbuyingselling Posted - 04/25/24

$CSTL new insider selling: 1126 shares. http://insiderbuyingselling.com/?t=CSTL

User Image AdiDasRom Posted - 04/24/24

$CSTL

User Image insiderbuyingselling Posted - 04/17/24

$CSTL new insider selling: 5210 shares. http://insiderbuyingselling.com/?t=CSTL

User Image IN0V8 Posted - 04/16/24

$CSTL Bought at open, $18

User Image Stock_Titan Posted - 04/11/24

$CSTL Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 https://www.stocktitan.net/news/CSTL/castle-biosciences-to-release-first-quarter-2024-financial-results-ltd6i08bnsbh.html

User Image insiderbuyingselling Posted - 04/10/24

$CSTL new insider selling: 2400 shares. http://insiderbuyingselling.com/?t=CSTL

User Image Stock_Titan Posted - 4 weeks ago

$CSTL Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer https://www.stocktitan.net/news/CSTL/presentations-at-eado-highlight-potential-impact-of-castle-jk7smnamjd84.html

User Image Stock_Titan Posted - 1 month ago

$CSTL Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/CSTL/castle-biosciences-to-present-at-the-23rd-annual-needham-virtual-6q3um7eu4q4g.html

User Image IN0V8 Posted - 1 month ago

$CSTL Guggenheim raises target price to $29 from $25 Scotiabank raises target price to $37 from $33

User Image AdiDasRom Posted - 03/26/24

$CSTL This company is growing slowly and surely.

User Image insiderbuyingselling Posted - 03/23/24

$CSTL new insider selling: 6336 shares. http://insiderbuyingselling.com/?t=CSTL

User Image Stock_Titan Posted - 03/22/24

$CSTL Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB https://www.stocktitan.net/news/CSTL/long-term-outcomes-data-shared-at-sso-2024-show-that-patients-with-a-avyqcm1mitis.html

User Image AdiDasRom Posted - 03/22/24

$CSTL

User Image Jiricek94 Posted - 03/20/24

$CSTL nice day, need more of these to get back to pre-earnings levels...

User Image AdiDasRom Posted - 03/19/24

$CSTL

User Image Stock_Titan Posted - 03/19/24

$CSTL Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy https://www.stocktitan.net/news/CSTL/leading-squamous-cell-carcinoma-practitioners-publish-consensus-ncieuhk3tbj4.html

User Image Stock_Titan Posted - 03/15/24

$CSTL New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older https://www.stocktitan.net/news/CSTL/new-study-shows-that-the-drug-drug-interactions-and-lifestyle-o7xxx5xppp3u.html

User Image AdiDasRom Posted - 03/14/24

$CSTL

User Image AdiDasRom Posted - 03/12/24

$CSTL

User Image Stock_Titan Posted - 03/12/24

$CSTL Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum https://www.stocktitan.net/news/CSTL/castle-biosciences-to-present-at-the-key-banc-capital-markets-es1x018jgzde.html

User Image Stock_Titan Posted - 03/08/24

$CSTL Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting https://www.stocktitan.net/news/CSTL/castle-biosciences-to-present-new-data-highlighting-the-clinical-73vumht9nj84.html

Analyst Ratings
Baird Outperform May 3, 24
Keybanc Overweight Mar 1, 24
Scotiabank Sector Outperform Mar 1, 24
Guggenheim Buy Dec 14, 23
Keybanc Overweight Aug 4, 23
Lake Street Buy Jul 7, 23
Stephens & Co. Overweight Jul 6, 23
BTIG Buy Jun 15, 23
Scotiabank Sector Outperform Jun 7, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Juvenal Tobin W Chief Commercial Off.. Chief Commercial Officer Jan 02 Option 2.89 6,701 19,366 46,857 01/04/24
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Dec 18 Sell 20.55 16,251 333,958 12,202 12/20/23
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Dec 12 Sell 20.11 8,432 169,568 13,879 12/14/23
BRADBURY DANIEL Director Director Dec 12 Sell 20.03 2,368 47,431 49,816 12/14/23
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Dec 08 Sell 20.1 4,852 97,525 14,325 12/12/23
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Dec 08 Option 0 54,283 133,327 12/12/23
BRADBURY DANIEL Director Director Dec 08 Sell 20.09 6,875 138,119 50,625 12/12/23
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Nov 24 Sell 20.03 600 12,018 16,305 11/28/23
BRADBURY DANIEL Director Director Nov 24 Sell 20.02 800 16,016 63,690 11/28/23
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Aug 03 Sell 20.1 600 12,060 17,391 08/07/23
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Jul 07 Sell 20.04 25,116 503,325 17,424 07/11/23
BRADBURY DANIEL Director Director Jul 07 Sell 20.39 50,000 1,019,500 67,805 07/11/23
Goldberg Ellen Director Director Jun 05 Buy 14.25 4,800 68,400 9,065 06/06/23
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Apr 12 Sell 22.64 8,372 189,542 20,908 04/14/23
BRADBURY DANIEL Director Director Jan 03 Sell 23.19 7,704 178,656 199,539 01/05/23
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Jan 03 Sell 22.9 8,958 205,138 25,093 01/05/23
Juvenal Tobin W Chief Commercial Off.. Chief Commercial Officer Nov 10 Option 2.38 3,700 8,806 9,049 11/14/22
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Sep 26 Sell 24.3 8,958 217,679 27,773 09/28/22
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Aug 29 Sell 29.71 10,359 307,766 28,525 08/31/22
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Aug 05 Sell 30.31 1,558 47,223 29,752 08/09/22
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Aug 01 Sell 27.28 8,959 244,402 30,170 08/03/22
BRADBURY DANIEL Director Director Aug 01 Sell 27.47 7,704 211,629 238,059 08/03/22
Olson Tiffany Director Director May 12 Buy 18.77 1,320 24,776 1,806 07/07/22
BRADBURY DANIEL Director Director Jan 04 Sell 43.47 16,053 697,824 130,930 06/13/22
BRADBURY DANIEL Director Director Mar 29 Sell 45.28 17,704 801,637 97,562 03/31/22
BRADBURY DANIEL Director Director Mar 14 Sell 37.56 17,704 664,962 102,562 03/16/22
BRADBURY DANIEL Director Director Feb 09 Sell 45.95 17,704 813,499 112,562 02/11/22
BRADBURY DANIEL Director Director Jan 24 Sell 35.44 14,631 518,523 117,562 01/26/22
BRADBURY DANIEL Director Director Jan 20 Sell 35.3 15,604 550,821 121,477 01/24/22
BRADBURY DANIEL Director Director Jan 18 Sell 35.25 2,470 87,068 125,651 01/20/22
BRADBURY DANIEL Director Director Nov 08 Sell 61.29 5,554 340,405 135,305 11/10/21
BRADBURY DANIEL Director Director Nov 04 Sell 61.18 4,446 272,006 136,693 11/08/21
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Oct 19 Sell 66.42 5,000 332,100 140,032 10/21/21
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Sep 15 Sell 75.03 3,333 250,075 148,365 09/15/21
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Sep 15 Sell 73.4 26,667 1,957,358 138,128 09/15/21
MAETZOLD DEREK J Pres. & Chief Exec... Pres. & Chief Exec. Officer Aug 19 Sell 59.57 12,500 744,625 376,018 08/19/21
BRADBURY DANIEL Director Director Aug 19 Sell 60.7 10,000 607,000 147,804 08/19/21